Details

Autor(en) / Beteiligte

• Mullish, Benjamin H
• Merrick, Blair
• Quraishi, Mohammed Nabil
• Bak, Aggie
• Green, Christopher A
• Moore, David J
• Porter, Robert J
• Elumogo, Ngozi T
• Segal, Jonathan P
• Sharma, Naveen
• Marsh, Belinda
• Kontkowski, Graziella
• Manzoor, Susan E
• Hart, Ailsa L
• Settle, Christopher
• Keller, Josbert J
• Hawkey, Peter
• Iqbal, Tariq H
• Goldenberg, Simon D
• Williams, Horace R T

Titel

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Ist Teil von

• Gut, 2024-07, Vol.73 (7), p.1-24

Ort / Verlag

England: BMJ Publishing Group Ltd and British Society of Gastroenterology

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• The first British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS)-endorsed faecal microbiota transplant (FMT) guidelines were published in 2018. Over the past 5 years, there has been considerable growth in the evidence base (including publication of outcomes from large national FMT registries), necessitating an updated critical review of the literature and a second edition of the BSG/HIS FMT guidelines. These have been produced in accordance with National Institute for Health and Care Excellence-accredited methodology, thus have particular relevance for UK-based clinicians, but are intended to be of pertinence internationally. This second edition of the guidelines have been divided into recommendations, good practice points and recommendations against certain practices. With respect to FMT for Clostridioides difficile infection (CDI), key focus areas centred around timing of administration, increasing clinical experience of encapsulated FMT preparations and optimising donor screening. The latter topic is of particular relevance given the COVID-19 pandemic, and cases of patient morbidity and mortality resulting from FMT-related pathogen transmission. The guidelines also considered emergent literature on the use of FMT in non-CDI settings (including both gastrointestinal and non-gastrointestinal indications), reviewing relevant randomised controlled trials. Recommendations are provided regarding special areas (including compassionate FMT use), and considerations regarding the evolving landscape of FMT and microbiome therapeutics.